Bristol Myers Squibb (CELG-RI) Revenue (2009 - 2026)
Bristol Myers Squibb (CELG-RI) reported Revenue of $11.5 billion for Q1 2026, up 2.57% year-over-year from $11.2 billion in Q1 2025, and down 8.1% quarter-over-quarter from $12.5 billion in Q4 2025.
Bristol Myers Squibb (CELG-RI) Revenue (2009 - 2026) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has 18 years of Revenue data on file, last reported at $11.5 billion in Q1 2026.
- Revenue for Q1 2026 came in at $11.5 billion, up 2.57% year-over-year; the trailing twelve-month figure through Mar 2026 was $48.5 billion (up 1.78% YoY), and the FY2025 annual result was $48.2 billion, changed 0.22% from the prior year.
- Revenue retreated to $11.5 billion in Q1 2026 per CELG-RI's latest filing, from $12.5 billion in the prior quarter.
- Over five years, Revenue peaked at $12.5 billion in Q4 2025 and troughed at $11.0 billion in Q3 2023.
- A 5-year average of $11.7 billion and a median of $11.6 billion in 2022 frame the typical range for Revenue.
- The sharpest annual moves came in 2024 and 2025: Revenue advanced 8.69% in 2024, then fell 5.6% in 2025.
- A 5-year view of Revenue shows it stood at $11.4 billion in 2022, then advanced by 0.62% to $11.5 billion in 2023, then advanced by 7.54% to $12.3 billion in 2024, then increased by 1.3% to $12.5 billion in 2025, then dropped by 8.1% to $11.5 billion in 2026.
- Business Quant data shows CELG-RI's Revenue at $11.5 billion in Q1 2026, $12.5 billion in Q4 2025, and $12.2 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 10.29 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 19.80 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 24.06 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 15.00 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 16.29 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 8.62 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 6.96 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 2.34 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 11.49 Bn |
| 10 | Bristol Myers Squibb | - | - | 8.07 Bn | 11.49 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11.49 Bn |
| Dec 31, 2025 | 12.50 Bn |
| Sep 30, 2025 | 12.22 Bn |
| Jun 30, 2025 | 12.27 Bn |
| Mar 31, 2025 | 11.20 Bn |
| Dec 31, 2024 | 12.34 Bn |
| Sep 30, 2024 | 11.89 Bn |
| Jun 30, 2024 | 12.20 Bn |
| Mar 31, 2024 | 11.87 Bn |
| Dec 31, 2023 | 11.48 Bn |
| Sep 30, 2023 | 10.97 Bn |
| Jun 30, 2023 | 11.23 Bn |
| Mar 31, 2023 | 11.34 Bn |
| Dec 31, 2022 | 11.41 Bn |
| Sep 30, 2022 | 11.22 Bn |
| Jun 30, 2022 | 11.89 Bn |
| Mar 31, 2022 | 11.65 Bn |
| Dec 31, 2021 | 11.99 Bn |
| Sep 30, 2021 | 11.62 Bn |
| Jun 30, 2021 | 11.70 Bn |